
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix is a biopharmaceutical company with a single segment focused on developing and commercializing therapeutic products for life-threatening diseases. The company's lead product, DefenCath, has shown positive results in reducing catheter-related bloodstream infections in hemodialysis patients. Cormedix also has potential for future growth through label expansion opportunities and its recent acquisition of Melinta assets. Key financial metrics to note are a forecasted ~$190M in peak non-risk adjusted sales for DefenCath in its current indication in 2030E and ~$220M in peak non-risk adjusted sales for Rezzayo in an expanded indication in 2034E. With strong data backing its products and multiple potential growth drivers, we believe Cormedix has a positive outlook for future success and revenue growth.
Bears say
Cormedix is facing several fundamental challenges, including a potential lack of differentiation in the safety profile of its lead product, DefenCath, compared to other prophylaxis options, as well as potential barriers to obtaining a broader label expansion. Additionally, the company's recent acquisition of Melinta could also create risks and challenges in terms of regulatory, commercial, and pricing pressures. Overall, these factors could impact the company's growth potential and generate uncertainty around its valuation, warranting a cautious outlook on the stock.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares